Xiaoping Wu and Jicheng Yang of Wanhuida Intellectual Property analyse an invalidation decision that addresses how dosage and administration features affect the inventiveness assessment of pharmaceuti ...

Junshi Biosciences has received acceptance from China’sNational Medical Products Administration (NMPA) for toripalimab ...

A new study published in the journal of BMC Nephrology showed that subcutaneous and intravenous epoetin showed similar ...

Risankizumab showed high rates of clinical remission and endoscopic response when administered as subcutaneous induction therapy for moderate to severe CD.

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous AdministrationKey ...

Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus A decision from the FDA on the updated application for Saphnelo SC is expected in the first half ...

The U.S. Food and Drug Administration (FDA) is reviewing an application seeking expanded approval of an under-the-skin injection version of Leqembi (lecanemab), called Leqembi Iqlik. Leqembi is an ...

Many professionals report awareness, but few actively prescribe the self-administered injectable contraceptive DMPA. HealthDay News — About one-third of health care professionals who are aware of ...

Significant predictors for prescribing DMPA-SC included being gender-diverse or male, having access to DMPA-SC-specific clinical workflows, and having state Medicaid and private insurance coverage for ...